Ovarian Cancer clinical trials in Pennsylvania

68 actively recruiting ovarian cancer trials at 66 sites across Pennsylvania.

Data from ClinicalTrials.gov · last refreshed 2026-07-07

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Regeneron Pharmaceuticals funds and runs this clinical trial (NCT04590326). In 2024, Regeneron Pharmaceuticals reported paying the doctors leading the trial a total of $2,601,553 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $2,601,553

Paid for research work on this trial

ROISIN O CEARBHAILL(oncologist on CancerDrs) $911,831
IRA WINER(oncologist on CancerDrs) $378,531
JOHN MORONEY(oncologist on CancerDrs) $324,562
JOHN HAYS(oncologist on CancerDrs) $259,971
KALYAN BANDA(oncologist on CancerDrs) $258,025

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Pennsylvania:

Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
Bryn Mawr Hospital — Bryn Mawr, Pennsylvania